ons

Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse

In keeping with the recent proliferation of rapid, easy-to-use diagnostic tests, many assays and collection products have entered the marketplace to help clinicians assess dosage appropriateness of therapeutic drugs and to screen for the presence of drugs of abuse. Some of these products require laboratory support while many simple test kits are suitable for point of care use by medical profe...

New Assays to Detect Disseminated Fungal Infections

Contributing Editor Harvard Medical School The yeast ) and pulmonary hypersensitivity (<...

Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.

The FDA approval of BiDil for heart failure in African American patients has underscored the concept that two patients can respond differently to the same medication. This concept holds true for a wide variety of everyday medications, and in many cases is due to individual gen...

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

Medical conventions are challenged every day. Already in the new year, the effectiveness of cold medicine and the gold standard in breast cancer treatment have been challenged. Standards in cholesterol testing are the latest casualty of medical innovation. For years, cholesterol has been measured by a simple panel o...

Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing

Since the first system was invented in 1957, blood gas analysis has revolutionized clinical medicine and patient care. During the 1960s, blood gas analysis became almost universally available, and blood gases were considered "the most important laboratory test for critically ill patients," according to a www.bloodgas.or...

Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology

MILWAUKEE, July 11, 2007 /PRNewswire/ -- A new study suggestsstrong variation in the occurrence of anaphylaxis between thenorthern and southern U.S. Anaphylaxis is a severe allergicreaction that can be fatal without treatment with epinephrine. Thestriking north-south differences in EpiPen prescribing, a marker ofanaphylaxis risk, currently are without explanation. Theinvestigators hypoth...

Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections

PHILADELPHIA, July 10, 2007 /PRNewswire-USNewswire/ -- After afirst childhood urinary tract infection (UTI), daily antibioticsmay not prevent another such infection, and may actually increasethe risk that the next urinary tract infection is caused byresistant bacteria, according to a new study in the July 11 issueof the Journal of the American Medical Association. In the first larg...

Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology

WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX NewsNetwork) -- Generex Biotechnology Corporation (Nasdaq:GNBT), theleader in drug delivery for metabolic diseases through the innerlining of the mouth, announced today that it will be making threeposter presentations at the 46th Annual Meeting of the EuropeanSociety of Pediatric Endocrinology in Helsinki, Finland June 27 --30, 200...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis

SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo,Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM(Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase2 trial looking at recombinant nematode anticoagulant protein c2(rNAPc2) in patients with acute coronary syndromes (ACS),preclinical data evaluating rNAPc2 in mouse models of colorectalcancer, and precli...

Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee

- Pain Reductions Observed at Eight Weeks Sustained up to 12 Weeksand Drug Remains Very Well Tolerated - SOUTH SAN FRANCISCO, Calif., July 02, 2007/PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminarylonger-term, follow-up results from a Phase 2 study showing that a1mg treatment with Adlea(TM) (formerly 4975) in patients withmoderate-to-severe osteoarthritis of the knee prod...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced today that it will present clinicaland preclinical data on its oral Factor Xa inhibitor and on itsintravenous and oral ADP receptor antagonist at the XXI Congress ofthe International Society of Thrombosis and Haemostasis (ISTH) inGeneva, Switzerland on July 6 through July 12, 2007. The EXPERT...

Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections

DENVER--(BUSINESS WIRE)--Jul 2, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused oninfectious disease and dermatology, today announced thatresearchers at the University of Pennsylvania led by Dr. PaulJanmey and Dr. Robert Bucki, in collaboration with Dr. Paul B.Savage of Brigham Young University, have demonstrated in a seriesof in vitro experiments tha...

Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

LONDON, June 28, 2007--A cervical cancer vaccine has shown 90%efficacy for prevention of cervical cancer and precancerous lesionsassociated with the human papillomavirus (HPV) types targeted bythe vaccine, conclude authors of an Article published early Onlineand in the upcoming issue of The Lancet. HPV types 16 and 18 account for 70% or morecases of cervical cancer worldwi...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection againstinfection with virus types beyond 16 and 18 with the GSK cervicalcancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Resultsfrom an interim analysis of a Phase III study show thatCERVARIX(R), the GlaxoSmithKline cervical cancer candidate vaccine,provides up to 100 percent protection against advanced prec...

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...

A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

Final Results from Exploratory Phase IIa Clinical Trial in Type 2Diabetes Patients Announced TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - TransitionTherapeutics Inc. ("Transition") , today announces the results fromits exploratory Phase IIa clinical trial indicating that 4-weeks ofdaily treatments with gastrin-based therapy, E1-I.N.T.(TM), showedsustained reductions in blood glucose co...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

-- Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company and A...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects CHICAGO, June 25 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company (NYSE: BMY...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trialanticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced the publication of preclinicalstudies, which demonstrate that treatment with pixantrone (BBR2778) resulted in minimal or no significant cardiotoxicity, whiledoxorubicin and mitoxantrone induced significant cardiac da...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

- BYETTA also Showed Sustained Improvements in Blood GlucoseControl and Progressive Weight Loss - CHICAGO, June 23, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. and Eli Lilly and Company today announcedresults from a study that showed BYETTA(R) (exenatide) injectionsustained improvements in blood sugar levels and progressive weightloss through three and a half years of thera...

BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting

Independent Study Indicates 20-50% Improvement in Post-PreservationFunctional Recovery of Peripheral Blood Stem Cells for CancerTherapy BOTHELL, Wash., June 25, 2007 /PRNewswire-FirstCall/ -- BioLifeSolutions Inc. , a leading developer and marketer of proprietaryhypothermic storage and cryopreservation media products for cells,tissues, and organs, today presented data from an independent...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range ofpatient populations, including varied ethnic groups, the elderly,and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea,reinforcing efficacy in combination with commonly used diabetesmedicines * Data confirm good tolerability in humans with studies showingincidence of sid...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...

VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - VIVUS, Inc.(NASDAQ: VVUS), a pharmaceutical company dedicated to thedevelopment and commercialization of novel therapeutic products,announced that Abstract #2209-PO, Evaluation of Glycemic Parametersin Obese Diabetic Patients Treated with Phentermine and Topiramate:Outcomes in a Private Practice Setting has been published in theAmerican...

Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos

New survey shows more than half of infertile couples willing todonate unused embryos for stem cell research BETHESDA, Md., June 20, 2007 /PRNewswire/ -- RESOLVE: TheNational Infertility Association issued the following statementtoday, in anticipation of President Bush's veto of federallegislation that would loosen current limitations on stem cellresearch: "President Bush is choosin...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- KeryxBiopharmaceuticals, Inc. today announced that abstracts related toSulonex(TM) (sulodexide oral gelcap) have been selected forpublication or presentation during the poster sessions scheduled totake place at the upcoming American Diabetes Association (ADA) 67thAnnual Scientific Sessions and exposition at the McCormick PlaceLakeside Cen...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.(OTCBB:NRGX) today announced the publication in the June 23 issueof the journal The Lancet of positive results from the first evergene therapy trial for Parkinson's disease and the first report ofdirect gene transfer into a patient's own brain cells for any adultneurodegenerative disease. The open label Phase 1 study, conduct...

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

Data from the PROactive and CHICAGO studies of ACTOS(R)(pioglitazone HCl) will be presented in poster format at the 67thScientific Sessions of the American Diabetes Association inChicago: -- Hospitalizations for serious adverse events in high-risk type 2 diabetes patients treated with pioglitazone for 3...

Nationwide MRSA Prevalence Study to Demonstrate Full Scope of 'Superbug' Threat Facing U.S. Healthcare Facilities and Patients

Broadest, Most Comprehensive Survey Provides New Benchmark on MRSAin Healthcare Facilities WASHINGTON, June 21, 2007 /PRNewswire-USNewswire/ -- Thefollowing was released today by APIC: WHAT: -- First nationwide study of the prevalence of Methicillin-resistant Staphylococcus aureus (MRSA), a virulent multi-drug resistant organism, in U.S. healthcare facilit...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, announced todaythat its proprietary Duocalin(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, Director ofScience and Preclinical D...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)Therapeutics, Inc. , a biopharmaceutical company focused on thetreatment of central nervous system disorders with an initial focuson obesity, today announced that the Company will present dataabout its lead obesity product candidate Contrave(TM) and itseffect on markers of cardiovascular disease (visceral fat, serumcholestero...

First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy

ROANOKE, Va.--(BUSINESS WIRE)--Jun 20, 2007 - Researchers from LunaInnovations Incorporated (NASDAQ: LUNA) and Virginia CommonwealthUniversity (VCU) are the first to show that carbon nanospheres,sometimes referred to as "buckyballs," are able to block allergicresponse in human cell culture experiments and mice. These findingsare described in a paper entitled "Fullerene Nanomaterials Inhibit...

Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions

PLYMOUTH MEETING, Pa., June 19, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that it will present a posteron trodusquemine (MSI-1436), its novel anti-obesity compound,during the American Diabetes Association (ADA) 67th ScientificSessions, June 22 to 25 in Chicago. The abstract, # 1801-P, is titled, "Trodusquemine is a MultiplePathway Inhibitor that Causes Diffe...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

Pharmacokinetic and Safety Profile of the Intramuscular Formulationof Peramivir Supports Further Evaluation as Treatment for AcuteInfluenza BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ --BioCryst Pharmaceuticals, Inc. presented results from two Phase Iclinical studies of an intramuscular (i.m.) formulation ofperamivir at the Options for the Control of Influenza Conference inTor...

VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC,a privately held biotechnology and healthcare product developmentcompany, announced today that its late-breaking abstract has beenaccepted as a poster presentation at the 67th Scientific Sessionsof the American Diabetes Association in Chicago, Ill. The abstract,entitled, "Effects of Timed Cycloset(TM) (A Quick ReleaseFormulat...